The abstract is read at the publisher; the summary is JClub's.
Tumor-associated epilepsy at diagnosis in glioblastoma is linked to better overall survival, with a hazard ratio of 0.81 (95% CI 0.69–0.99; P=0.036) and ~4–5 months advantage.
- Why it matters: The prognostic value of tumor-associated epilepsy in glioblastoma is unclear, and it is unknown whether seizure status reflects distinct tumor biology or modifies how surgery affects outcomes.
- What they did: In a retrospective multicenter test cohort of 855 patients (Aachen, Hamburg, Bielefeld) and a prospective validation cohort of 344 patients (Erlangen), survival was modeled with Cox regression and propensity matching, alongside methylation profiling, epigenetic deconvolution, spatial transcriptomics, and electrogenomics.
- The result: The survival association persisted in validation (C-index 0.68; 95% CI 0.62–0.74) and propensity-matched analyses (HR 0.74, 95% CI 0.56–0.96; P=0.027), and TAE defined an inflammatory, immune-related molecular subgroup.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.